Novo Nordisk acquires Korean approval of ‘Saxenda,’ GLP-1 analogue obesity treatment

Published: 2017-07-27 16:27:00
Updated: 2017-07-27 16:08:21

Novo Nordisk Korea(President Rana Azfar Zafar) announced that Saxenda(generic name: liraglutide), its new obesity therapy, was approved from the Ministry of Food and Drug Safety on the 21st.

Saxenda is the world’s obesity therapy approved as GLP-1(Glucagon-Like Peptide 1) analogue.

According to...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.